Treatment improved patient reported outcomes, reduced viral load, and maintained lung function compared to placebo; Multi-center, international trial slated for 2026 Dr. Brett Giroir, Chief Executive ...

COLLEGE PARK, Ga., May 7, 2025 /PRNewswire/ -- Altesa BioSciences today announced positive topline results from its Phase 2 placebo-controlled study examining the effects of vapendavir in COPD ...

VirTus Respiratory Research Ltd, a leading respiratory-focused contract research organisation (CRO), today announced that results from their human rhinovirus challenge model in patients with chronic ...

The MarketWatch News Department was not involved in the creation of this content. Study will begin enrollment in Q1 2026 in the US and UK and leverage the BIOFIRE(R) SPOTFIRE(R) point-of-care ...

Please provide your email address to receive an email when new articles are posted on . Rhinovirus was the most common virus (29%). Treatment with high-dose corticosteroids increased odds for ...

Antiviral improved overall patient-reported measures of both upper, lower respiratory symptoms, shortened overall course of illness COLLEGE PARK, Ga., May 7, 2025 /PRNewswire/ -- Altesa BioSciences ...

Rhinovirus infections are responsible for approximately half of acute exacerbations of COPD, and it is hypothesized that early treatment of rhinovirus infections may prevent respiratory complications ...

Treatment improved patient reported outcomes, reduced viral load, and maintained lung function compared to placebo; Multi-center, international trial slated for 2026 AMSTERDAM, Sept. 28, 2025 ...

Study will begin enrollment in Q1 2026 in the US and UK and leverage the BIOFIRE® SPOTFIRE® point-of-care diagnostics platform at U.S. sites ATLANTA and SALT LAKE CITY, Sept. 9, 2025 /PRNewswire/ -- ...